Thermo Fisher Completes $1.1B Sale of Microbiology Unit to Astorg

Key Facts

In a move reflecting large-cap strategies to restructure investment portfolios, Thermo Fisher Scientific has completed the sale of its microbiology unit to European private equity firm Astorg for $1.1 billion in cash. This divestiture aims to fund shareholder value initiatives and reallocate capital toward other segments, while the unit will operate as an independent entity under new leadership. According to reports, this exit allows the unit, which provides clinical and pharmaceutical testing equipment, to pursue growth and innovation independently.

The transaction comes as Thermo Fisher seeks to enhance financial efficiency, with the microbiology unit having generated $645 million in revenue in 2025, a 2% year-over-year increase. Per market data, TMO shares closed at $603.01 (close August 12, 2026), while the German-listed TN8.DE stood at 520.40 EUR (close August 12, 2026). The company continues to face competition in this space from major players such as Danaher, Merck, and Waters.

Investors are currently monitoring stock stability following the deal's closure, with TMO closing at $603.01 on August 12, 2026, within a daily range of $595 to $604.19. Looking at the economic calendar, there are no direct upcoming catalysts for the company in the next seven days; however, markets remain attentive to global inflation data that could impact risk appetite in the healthcare and diagnostics sector.